Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

Open access
Rodbard, Helena W., Rosenstock, Julio, Canani, Luis H., Deerochanawong, Chaicharn, Gumprecht, Janusz, Lindberg, Søren Østergaard, Lingvay, Ildiko, Søndergaard, Anette Luther, Treppendahl, Marianne Bach, Montanya, Eduard, PIONEER 2 Investigators, Cruz, Pablo, Loredo, Luis De, Luquez, Cecilia, Moisello, Maria, Augusto, Gustavo Akerman, Castro, Marise, Canani, Luis, Akrap, Branko, Bulum, Tomislav, Rahelic, Dario, Sunic-Grcic, Ivana, Tusek, Srecko, Avramidis, Iakovos, Benroubi, Marian, Didangelos, Triantafyllos, Karousos, Gerasimos, Pagkalos, Emmanouil, Sampanis, Christos, Somali, Maria, Domboróczki, Zsolt, Faludi, Péter, Gaál, Zsolt, Kis-Gombos, Piroska, Kocsis, Gyozo, Marton, Zoltán, Sudár, Zsolt, Buscemi, Silvio, Di Carlo, Alberto, Dotta, Francesco, Gambineri, Alessandra, Lauro, Davide, Maranghi, Marianna, Arciszewska, Malgorzata, Gumprecht, Janusz, Matuszewska, Krystyna, Skokowska, Ewa, Stasinska, Teresa, Feofanova, Svetlana, Filippova, Ekaterina, Galstyan, Gagik, Gaysina, Leylya, Kunitsyna, Marina, Suplotova, Lyudmila, Antic, Slobodan, Djukic, Aleksandar, Mitrovic, Milena, Pesic, Milica, Stokic, Edita, Jodar, Esteban, Martínez, Encarna, Raya, Pedro Mezquita, Montanya, Eduard, Portillo, Cristobal Morales, Vera, Mercè Pérez, Fernández, Margarita Rivas, San Jose, Patricia, Riera, Manel Terns, Boonyavarakul, Apussanee, Deerochanawong, Chaicharn, Sriwijitkamol, Apiradee, Ajani, Dilawar, Armas, Eddie, Barbel-Johnson, Kim, Bartilucci, Darlene, Bonabi, Gholamreza, Busch, Robert, Butuk, David, Cannon, Kevin, Chase, Craig, Chaykin, Louis, Cheekati, Vasundhara, Davis, Thomas, Delgado, Belkis, Farris, Neil, Graves, Mark, Ha, Chi, Harper, Linda, Herring, Sharon, Hewitt, Mitzie, Hsia, Daniel, Jackson, Richard, Jardula, Michael, Joyce, Mark, Juarez, Mario, Kapoor, Anoop, Karounos, Dennis, Kayne, David, Lacour, Audrey, Ledesma, Gilbert, Lingvay, Ildiko, Lipetz, Robert, Lomboy, Joseph, Lynd, Sean, Morawski, Emily, Morin, Robert, Murphy, Richard, Overcash, J. Scott, Pullman, John, Rodbard, Helena W., Rosenstock, Julio, Ruoff, Gary, Steenkamp, Devin, Toro, Hugo, Trachtenbarg, David, Tulloch, Brian, Weisbrot, Albert, Wright, Alison · 2019 · Diabetes Care

Abstract

OBJECTIVE: Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AND METHODS: Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product without rescue medication) in all randomized patients. RESULTS: Four hundred (97.1%) patients in the oral semaglutide group and 387 (94.4%) in the empagliflozin group completed the trial. Oral semaglutide provided superior reductions in HbA1c versus empagliflozin at week 26 (treatment policy –1.3% vs. –0.9% [–14 vs. –9 mmol/mol], estimated treatment difference [ETD] –0.4% [95% CI –0.6, –0.3] [–5 mmol/mol (–6, –3)]; P < 0.0001). The treatment difference in HbA1c significantly favored oral semaglutide at week 26 for the trial product estimand (–1.4% vs. –0.9% [–15 vs. –9 mmol/mol], ETD –0.5% [95% CI –0.7, –0.4] [–6 mmol/mol (–7, –5)]; P < 0.0001) and at week 52 for both estimands (P < 0.0001). Superior weight loss was not confirmed at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product −4.7 vs. −3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide. CONCLUSIONS: Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc19-0883

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Cited by

See all 482

Metadata

Authors
Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., PIONEER 2 Investigators, Cruz, P., Loredo, L. D., Luquez, C., Moisello, M., Augusto, G. A., Castro, M., Canani, L., Akrap, B., Bulum, T., Rahelic, D., Sunic-Grcic, I., Tusek, S., Avramidis, I., Benroubi, M., Didangelos, T., Karousos, G., Pagkalos, E., Sampanis, C., Somali, M., Domboróczki, Z., Faludi, P., Gaál, Z., Kis-Gombos, P., Kocsis, G., Marton, Z., Sudár, Z., Buscemi, S., Di Carlo, A., Dotta, F., Gambineri, A., Lauro, D., Maranghi, M., Arciszewska, M., Gumprecht, J., Matuszewska, K., Skokowska, E., Stasinska, T., Feofanova, S., Filippova, E., Galstyan, G., Gaysina, L., Kunitsyna, M., Suplotova, L., Antic, S., Djukic, A., Mitrovic, M., Pesic, M., Stokic, E., Jodar, E., Martínez, E., Raya, P. M., Montanya, E., Portillo, C. M., Vera, M. P., Fernández, M. R., San Jose, P., Riera, M. T., Boonyavarakul, A., Deerochanawong, C., Sriwijitkamol, A., Ajani, D., Armas, E., Barbel-Johnson, K., Bartilucci, D., Bonabi, G., Busch, R., Butuk, D., Cannon, K., Chase, C., Chaykin, L., Cheekati, V., Davis, T., Delgado, B., Farris, N., Graves, M., Ha, C., Harper, L., Herring, S., Hewitt, M., Hsia, D., Jackson, R., Jardula, M., Joyce, M., Juarez, M., Kapoor, A., Karounos, D., Kayne, D., Lacour, A., Ledesma, G., Lingvay, I., Lipetz, R., Lomboy, J., Lynd, S., Morawski, E., Morin, R., Murphy, R., Overcash, J. S., Pullman, J., Rodbard, H. W., Rosenstock, J., Ruoff, G., Steenkamp, D., Toro, H., Trachtenbarg, D., Tulloch, B., Weisbrot, A., & Wright, A.
Affiliations
  • Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
  • Novo Nordisk (Denmark) (DK)
Venue
Diabetes Care
Published
2019-10-07
Volume
42
Issue
12
Pages
2272-2281
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2974621372
Cited by
463
References
37
Citations by year
2026: 53 · 2025: 85 · 2024: 78 · 2023: 55 · 2022: 64 · 2021: 59 · 2020: 60 · 2019: 8
FWCI
38.76
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
  • Use Siena air (University of Siena) (submittedVersion)
  • Lume (Universidade Federal do Rio Grande do Sul) (submittedVersion, cc-by-nc-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
oral semaglutide, empagliflozin, type 2 diabetes, metformin failure, GLP-1 receptor agonists, SGLT2 inhibitors, glycemic control, HbA1c, weight loss, gastrointestinal adverse effects, drug safety, treatment policy estimand
MeSH terms
Semaglutide, Administration, Oral, Adult, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Weight Loss, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. https://app.cochat.ai/papers/10.2337/dc19-0883
The paper
Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., PIONEER 2 Investigators, Cruz, P., Loredo, L. D., Luquez, C., Moisello, M., Augusto, G. A., Castro, M., Canani, L., Akrap, B., . . . Wright, A. (2019). Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. https://doi.org/10.2337/dc19-0883

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.